Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 1.00 |
| ▸ | TDO2 | P48775 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808082 | 1.00 | IDO1 (1.00) | IDO1TDO2POLBHPGDHTT | |
| SCHEMBL2520579 | 0.88 | IDO1 (0.79) | IDO1TDO2POLBHPGDHTT | |
| SCHEMBL2516741 | 0.88 | IDO1 (0.81) | IDO1TDO2POLBHPGDHTT | |
| SCHEMBL2512654 | 0.88 | IDO1 (0.78) | IDO1TDO2POLBHPGDHTT | |
| SCHEMBL20585913 | 0.86 | IDO1 (1.00) | IDO1TDO2POLBHPGD | |
| SCHEMBL149917 | 0.86 | IDO1 (1.00) | IDO1TDO2POLBHPGD | |
| SCHEMBL2518277 | 0.85 | IDO1 (0.74) | IDO1TDO2POLBHPGDHTT | |
| SCHEMBL2519342 | 0.85 | IDO1 (0.74) | IDO1TDO2POLBHPGDHTT | |
| SCHEMBL5631847 | 0.84 | IDO1 (0.73) | IDO1TDO2 | |
| SCHEMBL2512553 | 0.84 | IDO1 (1.00) | IDO1TDO2POLBHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 839 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | BioAlta, LLC | 2024-10-17 | — | — | US | claimed |
| US-20240307516-A1 | COMBINATION THERAPY FOR CANCER | IO BIOTECH APS (DK) | 2024-09-19 | — | — | US | claimed |
| EP-3693009-B1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | claimed |
| EP-4316517-A2 | COMBINATION THERAPY AGAINST CANCER | IO Biotech ApS (DK) | 2024-02-07 | — | — | EP | claimed |
| EP-4308241-A1 | COMBINATION THERAPY FOR CANCER | IO Biotech ApS (DK) | 2024-01-24 | — | — | EP | claimed |
| EP-3560959-B1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-11-22 | — | — | EP | claimed |
| CN-109152830-B | Core/shell structural platform for immunotherapy | 卫理公会医院 | 2023-11-03 | — | — | CN | claimed |
| US-11786457-B2 | Peritumoral and intratumoral materials for cancer therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-17 | — | — | US | claimed |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-10-03 | — | — | US | claimed |
| US-20230032934-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | MYST THERAPEUTICS, LLC (US) | 2023-02-02 | — | — | US | claimed |
| WO-2021016534-A2 | ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF | AGENUS INC. (US) | 2021-01-28 | — | — | WO | claimed |
| WO-2021016531-A1 | ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF | AGENUS INC. (US) | 2021-01-28 | — | — | WO | claimed |
| EP-3294324-A1 | VACCINES FOR TREATMENT AND PREVENTION OF CANCER | Agenus Inc. (US) | 2018-03-21 | — | — | EP | claimed |
| WO-2016183486-A1 | VACCINES FOR TREATMENT AND PREVENTION OF CANCER | AGENUS INC. (US) | 2016-11-17 | — | — | WO | claimed |
| US-20160331821-A1 | VACCINES FOR TREATMENT AND PREVENTION OF CANCER | AGENUS INC. | 2016-11-17 | — | — | US | claimed |
| EP-3085697-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Holdings Corporation (US) | 2016-10-26 | — | — | EP | claimed |
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2014-12-25 | — | — | US | claimed |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2013-05-16 | — | — | US | claimed |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-12-22 | — | — | US | claimed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786457-B2 | Peritumoral and intratumoral materials for cancer therapy | CD47, CD68, GZMB | IDO1 59/4885TDO2 2375/4885POLB 2684/4885 |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR6 | IDO1 1877/4885TDO2 1919/4885POLB 4547/4885 |
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | CD274, PDCD1LG2, PDCD1 | IDO1 475/4885TDO2 3215/4885POLB 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.